ABSTRACT
The use of atypical antipsychotics (APs) is associated with increased mortality in those with dementia and parkinsonism. [1] [2] [3] The prevalence of psychosis in those with Parkinson's disease has been reported to be as high as 60%. 4, 5 Therefore, clinicians face a quandary of whether to address the psychosis with a medication that may lead to premature death.
Past studies have reported a high incidence of the use of APs in those with parkinsonism, but the prevalence has never been reported. [6] [7] [8] [9] Prevalence data are important for population-based health care planning.
In this study, we determined the point prevalence for the use of APs among all persons with Parkinson's disease in Olmsted County, Minnesota. In addition, we investigated the total duration of AP use and the disease duration, indication, prevalence of dementia, and residence at initiation of AP therapy.
Patients and Methods

Study Population and Case Ascertainment
Extensive details about our population and case ascertainment have been reported elsewhere. [10] [11] [12] [13] [14] [15] [16] In brief, we studied the prevalent cases of Parkinson's disease in the geographically defined population of Olmsted County, Minnesota, on the prevalence day of 1 January 2006.
Diagnostic Criteria
Criteria for parkinsonism have been described elsewhere. [10] [11] [12] [13] [14] [15] Among the patients who fulfilled the criteria for parkinsonism, we applied the diagnostic criteria in Table 1 . In this study, we measured the prevalence of AP use in patients with Parkinson's disease both with and without dementia. Therefore, we considered those with Parkinson's disease without dementia (PD), dementia with Lewy bodies (DLB), Parkinson's disease with dementia (PDD), and Parkinson's disease/other dementia (PD/OD). Determining AP use in other types of parkinsonism (e.g., MSA or PSP) was beyond the scope of this study. 
Data Collection
To identify patients taking APs on the prevalence day, we used two sources. First, the Rochester Epidemiology Project collects information on all medications prescribed electronically (county-wide practice since 2003). Second, we had access to the full clinical notes and medication reconciliation history of patients through the medical record.
Although many patients had multiple indications for AP use, we categorized indications into a hierarchical ranking: 
Results
There were 296 patients with Parkinson's disease in Olmsted County on the prevalence day: 187 (63.2%) men and 109 (36.8%) women. The prevalence of AP use is shown in Table 2 . The overall prevalence of AP use was 9.8% (29 of 296). The prevalence in men was 9.1% (17 of 187) and in women was 11.0% (12 of 109; P for difference 5 0.69). The median age on prevalence day for those taking APs was 80.4 years overall (IQR, 75.8-83.6) and was similar in men (80.4; IQR, 75.8-83.6) and women (80.0; IQR, 75.8-83.6; P for difference 5 0.91).
The most common AP used was quetiapine (n 5 24) with a median daily dose of 62.5 mg (IQR, 25-125). Three subjects used olanzapine (total daily doses of 2.5, 5.9, and 7.5 mg), and 2 subjects used risperidone (total daily doses of 0.5 and 5 mg).
The pair-wise differences in AP use between PD and other subtypes with dementia were all statistically significant (PDD vs. PD, P < 0.0001; DLB vs. PD, P < 0.0001; PD/OD vs. PD, P 5 0.01). By contrast, the pair-wise differences in AP use between the categories with dementia were not statistically significant (PDD vs. DLB, P 5 0.17; PDD vs. PD/OD, P 5 0.99; DLB vs. PD/OD, P 5 0.30).
Of note, 96.5% (28 of 29) of those on APs suffered from dementia. The 1 patient without dementia had an intellectual disability and bipolar disorder.
The median time of AP initiation was 4.87 years (IQR, 2.63-8.38) after motor parkinsonism in 89.7% (26 of 29) of cases. In 3 patients, the AP was initiated before motor parkinsonism for psychiatric indications.
The median duration of AP use was 3.74 years (IQR, 2.55-5.56) in 23 of 29 cases (6 were unknown); however, 7 of the 23 cases (30.4%) used APs only intermittently through that time frame. The median time between initiation of the AP and death was 3.74 years (IQR, 2.83-6.30). Persons taking APs on the The most frequent indication for AP use was psychosis or behavior that was threatening to the subject or others (71.4%; 20 of 28 cases). In 14.3% (4 of 28) of patients, there was another psychiatric indication. In 1 patient with psychosis, the AP was used to avoid nursing home placement. There were only 3 patients (10.7%; 3 of 28) with psychosis or bothersome behavior without documentation of a clear threat to self or others. One patient had an unknown indication.
Most patients (15 of 27; 55.6%) resided in a skilled nursing facility at the time of AP initiation; however, 12 patients (12 of 27; 44.4%) resided in a private home. Of these 12, 3 remained at home for the remainder of their life, 8 eventually moved to a skilled nursing facility, and the current residential status of 1 was unknown. The median time to placement in a nursing facility after initiation of AP use was 0.57 years (IQR, 0.46-1.74).
Discussion
We found that 9.8% of persons with Parkinson's disease were taking APs in our population on the prevalence day. To our knowledge, this is the first report of prevalence of AP use in those with Parkinson's disease. Three other studies reported a cumulative probability of taking APs of 25% by 5 years, 7 35% by 7 years, 6 and 51% by 6 years. 8 Our rate of AP use is surprisingly low compared to these reports. Our use of prevalence, instead of cumulative probability, could explain this lower rate. This would be true if there is a high mortality rate soon after starting APs, or if persons use the APs only briefly. However, our data do not support that. We are currently studying the cumulative probability of AP use in our population to clarify this discrepancy.
Quetiapine was the most common AP used on our prevalence day of 1 January 2006. We have no reason to suspect that this pattern has substantially changed since then. No typical APs were used. A recent report has shown a higher risk of death in persons using typical versus atypical APs, and that quetiapine has the lowest risk among the atypical class. 3 We found that 96.5% of those with Parkinson's disease taking APs also had dementia. This is not surprising, but is considerably different from the findings in two past reports. One study reported that <10% of those with Parkinson's disease who initiated AP therapy were diagnosed with dementia. 3 Another study reported that 47% of Parkinson's disease patients prescribed APs did not have dementia. 9 This discrepancy needs further study.
There is an increased risk of death in those with Parkinson's disease taking APs. 2, 3 Although pimavanserin was approved for Parkinson's disease psychosis in 2016, it also carries the black box warning of increased death for those with dementia-related psychosis. In our study, we found that 89.3% (25 of 28) Values reported as median (25th percentile, 75th percentile). None of the comparisons between non-AP users and AP users overall or separately within a sex were statistically significant for either age on prevalence day or duration of disease (all P values for Wilcoxon rank-sum tests > 0.05).
P R E V A L E N C E O F A N T I P S Y C H O T I C U S E I N P D
of cases on APs had an indication with a reasonable risk-benefit ratio. Specifically, the patients had a comorbid psychiatric disease, a threatening psychosis or behavior, or the AP was prescribed to avoid nursing home placement. In summary, the use of APs in patients with Parkinson's disease should be judicious, and reserved for those in which the family and physician feel the risk-benefit balance is justified. Prescribing an acetylcholinesterase inhibitor first could reduce the hallucinations and prevent the need for an AP.
In spite of their disability with Parkinson's disease, dementia, and psychosis, 44.4% of those starting APs resided at home. Unfortunately, 72.7% (8 of 11) of those eventually moved to a skilled nursing facility within a median time of only 0.57 years after starting the AP. This undoubtedly reflects the difficult burden of these severely affected individuals on the caregiver.
Our study has several strengths. Because we were able to study the entire population of Olmsted County, referral bias was not a concern. Also, we were able to use two complementary sources for medication information. More importantly, we were able to study the medical records of all the patients to get important details on their use of APs.
Our study also had limitations. Because of its population-based design, the power is limited by smaller numbers of cases than studies using large Last, 3 of our cases started APs before the onset of their motor parkinsonism, possibly suggesting that they could have suffered from drug-induced parkinsonism. One patient had Alzheimer's dementia with psychosis and eventually discontinued the AP, but continued with parkinsonism for many years. The other 2 patients were on APs for bipolar disorder, but eventually developed clinical symptoms consistent with PD and DLB. Although the APs were never discontinued, their disease progressed in a typical way, so we elected to include them in this study. If we had excluded these 3 patients, the prevalence rate for AP use in those with Parkinson's disease would have been lower.
